Companies work to develop combo mAb, NK cell COVID-19 therapy
A new research project is bringing together universities and pharmaceutical companies to collaborate on the development of a combination of a monoclonal antibody (mAb) and natural killer (NK) cells as a treatment for COVID-19. The efforts are spearheaded by Harbour BioMed and expand on the company's work in using mAb against SARS-CoV-2. Read More
Regeneron, Roche increase supply of COVID-19 antibody cocktail
Regeneron Pharmaceuticals and Roche are joining forces to develop, manufacture, and distribute Regn-COV2, Regeneron's investigational antiviral antibody cocktail against COVID-19. The collaboration is expected to increase supply of the drug to 3.5 times the current capacity. Read More
Bio-Techne, Leica launch RNA probes for COVID-19 research
Bio-Techne and Leica Biosystems have announced the automation of RNAscope COVID-19 probes on Bond Rx, Leica's staining platform, for research use only. This gives researchers the ability to automate COVID-19 research protocols, reduce labor, and speed up turnaround times. Read More
BioSymetrics, Janssen, Sema4 use AI to predict COVID-19
BioSymetrics, Sema4, and Janssen Pharmaceuticals will use artificial intelligence (AI) to predict the onset and severity of COVID-19 among different populations. Read More
Qiagen expands genomic tools for COVID-19 research
Qiagen launched a SARS-CoV-2 primer panel that converts viral RNA samples into libraries that are ready for next-generation sequencing of the novel coronavirus genome. Read More
Agilent expands molecule manufacturing capacity
Agilent Technologies said that it's expanding its Frederick, CO-based production facility to more than double its current capacity for developing the short DNA and RNA molecules used to create nucleic acid-based therapeutics. Read More
Carma Cell Therapies expands phase I trial of cell therapy
Carma Cell Therapies said it has expanded the phase I trial of its Mcy-M11 lead anti-mesothelin messenger RNA chimeric antigen receptor- peripheral blood mononuclear cell cell-therapy candidate to include a new parallel cohort of patients and two additional clinical sites. Read More
Eli Lilly, Innovent expand immuno-oncology licensing
Eli Lilly and Innovent Biologics have agreed to a global expansion of their strategic alliance for Tyvyt (sintilimab injection), an anti-programmed cell death 1 monoclonal antibody immuno-oncology drug codeveloped and cocommercialized by the companies in China. Read More
AgilVax gets $1.2M to advance antibody-based therapy
AgilVax has been awarded a $1.2 million Fast Track Small Business Innovation Research grant by the U.S. National Cancer Institute to study a vaccine candidate. Read More
Therapure to manufacture VBI coronavirus vaccines
Therapure Biomanufacturing has signed an agreement with VBI Vaccines for the manufacture of its coronavirus vaccine candidates. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
